Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.

Leger PD, Johnson DH, Robbins GK, Shafer RW, Clifford DB, Li J, McLaren PJ, Haas DW.

J Neurovirol. 2014 Jun;20(3):304-8. doi: 10.1007/s13365-014-0235-9. Epub 2014 Feb 20.

PMID:
24554482
[PubMed - in process]
2.

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.

Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA.

AIDS. 2005 Sep 2;19(13):1341-9.

PMID:
16103764
[PubMed - indexed for MEDLINE]
3.

Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.

Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW.

AIDS. 2006 Jul 13;20(11):1503-13.

PMID:
16847405
[PubMed - indexed for MEDLINE]
4.

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.

J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.

PMID:
20942650
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.

French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D; OzCombo 2 investigators.

HIV Clin Trials. 2002 May-Jun;3(3):177-85. Erratum in: HIV Clin Trials 2002 Nov-Dec;3(6):following table of contents.

PMID:
12032876
[PubMed - indexed for MEDLINE]
6.

A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals.

McCarthy WF, Gable J, Lawrence J, Thompson M; AIDS Research Consortium of Atlanta ASD Investigators.

Pharmacoepidemiol Drug Saf. 2000 Jan;9(1):49-53. doi: 10.1002/(SICI)1099-1557(200001/02)9:1&lt;49::AID-PDS465&gt;3.0.CO;2-C.

PMID:
19025802
[PubMed]
7.

Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE Jr, Abrams EJ, Mofenson LM.

Pediatrics. 1999 May;103(5):e62.

PMID:
10224206
[PubMed - indexed for MEDLINE]
8.

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535. Review.

PMID:
16625606
[PubMed - indexed for MEDLINE]
9.

Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.

Kelleher T, Cross A, Dunkle L.

Clin Ther. 1999 Jul;21(7):1182-92.

PMID:
10463516
[PubMed - indexed for MEDLINE]
10.

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.

AIDS. 1999 Apr 16;13(6):685-94.

PMID:
10397563
[PubMed - indexed for MEDLINE]
11.

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.

Moore RD, Wong WM, Keruly JC, McArthur JC.

AIDS. 2000 Feb 18;14(3):273-8.

PMID:
10716503
[PubMed - indexed for MEDLINE]
12.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

PMID:
19282782
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.

Van Dyke RB, Wang L, Williams PL; Pediatric AIDS Clinical Trials Group 219C Team.

J Infect Dis. 2008 Dec 1;198(11):1599-608. doi: 10.1086/593022.

PMID:
19000014
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.

Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, Alcami J.

J Med Virol. 2009 Feb;81(2):211-6. doi: 10.1002/jmv.21377.

PMID:
19107982
[PubMed - indexed for MEDLINE]
15.

Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.

Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701.

PMID:
15167288
[PubMed - indexed for MEDLINE]
16.

ddI and d4T plus protease inhibitors.

[No authors listed]

GMHC Treat Issues. 1996 Nov;10(11):8-9.

PMID:
11364012
[PubMed - indexed for MEDLINE]
17.

Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.

Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R; ANRS 12-06/IMEA 012 Trial Study Group.

MedGenMed. 2007 Oct 9;9(4):7.

PMID:
18311357
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.

PMID:
10983647
[PubMed - indexed for MEDLINE]
19.

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

Shlay JC, Visnegarwala F, Bartsch G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan S; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):147-55.

PMID:
15671799
[PubMed - indexed for MEDLINE]
20.

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.

Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.

AIDS. 1998 Aug 20;12(12):1513-9.

PMID:
9727573
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk